欧莱雅的“进击”

Core Viewpoint - L'Oréal is actively expanding its market presence through acquisitions and investments, particularly focusing on the medical aesthetics sector, in response to slowing growth in its core beauty business [2][9]. Group 1: Acquisitions and Investments - L'Oréal has acquired an additional 10% stake in Galderma, increasing its ownership to 20%, following an initial investment in 2024 [3]. - The company recently invested €4 billion to acquire beauty licenses for several luxury brands from Kering Group, including Creed and others, with a total agreement value of €40 billion [6]. - L'Oréal has also invested in domestic skincare brands, including a stake in Naturals and a minority investment in LAN [6]. Group 2: Medical Aesthetics Focus - The acquisition of Galderma is seen as a strategic move to enhance L'Oréal's presence in the medical aesthetics market, which includes skincare and aesthetic treatments [4]. - Galderma's product offerings, such as Restylane and Sculptra, have gained regulatory approval in China, indicating a strong market potential [3]. - L'Oréal's CEO emphasized the importance of the aesthetics business as a key extension of their core beauty operations, aiming to deepen collaboration with Galderma [3]. Group 3: Financial Performance - L'Oréal's sales for the first three quarters of the year reached €32.8 billion, reflecting a growth rate of approximately 1.2%, a decline from the previous year's 6% [9]. - The company's sales in the North Asia market, including China, saw a decline of 1.1% to €5.39 billion in the first half of 2025 [9]. - Overall, L'Oréal's projected sales growth for 2024 is 5.1%, significantly lower than the growth rates of 18.5% and 7.6% in 2022 and 2023, respectively [9].